Live Chat

Perdagangan Gilead GILD

Gilead diagram langsung

Dasar-dasar Instrumen

Weekly Search
Weekly
Daily
Tanggal Tutup Ubah Ubah (%) Buka Tinggi Rendah

Berita

Info

Spread

0.57

Spread (%)

0.6213 %

Leverage

1:10

Bunga Overnight Beli

-0.0597 %

Bunga Overnight Jual

-0.0292 %

Mata Uang

USD

Jam Trading

Pasar tutup

Jumat

14:31 - 20:59

Senin

14:31-20:59

Selasa

14:31-20:59

Rabu

14:31-20:59

Kamis

14:31-20:59

Analisis dan Statistik

Buka

---

Sebelumnya Tutup

---

52 Minggu Tigg/Rdh

--- – ---

Kapitalisasi Pasar

117585453056

Saham yang Beredar

1246000000

Tanggal Penghasilan (Berikutnya)

2013-01-28

Hasil Div

2024-09-27

Tanggal Non-Dividen

2024-12-13

Proyeksi tingkat dividen tahunan

3.08

Proyeksi hasil dividen tahunan

0.0326

EPS

0.09

Pelajari lebih lanjut tentang instrumen ini

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Berita Terkini

Ikuti terus berita keuangan terkini dari seluruh dunia.

Kamis, 14 November 2024

Dogecoin surges after Elon Musk issues crypto endorsement

Nvidia Blackwell AI Chips

Kamis, 14 November 2024

Week ahead: Tech rally hinges on Nvidia earnings

Dogecoin surges

Rabu, 13 November 2024

Dogecoin surges as Trump unveils new government efficiency initiative with Musk andRamaswamy

Rabu, 13 November 2024

Japanese Yen to USD: Yen drops to fresh multi-month low against USD

Rabu, 13 November 2024

Asia markets today: Nikkei 225 up 0.18%, Hang Seng Index falls by 197 points

Selasa, 12 November 2024

UK stock market news: Helium One share price trading 16.1% higher

Selasa, 12 November 2024

Leveraged ETF to package Warren Buffett's Berkshire Hathaway B stock

Selasa, 12 November 2024

Dogecoin surges 20% after Department of Government Efficiency announcement

Trustpilot
Live Chat